Cargando…

Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care

OBJECTIVES: To study the impact of treatment strategy on achieving and sustaining disease-modifying antirheumatic drug (DMARD)-free remission in patients with rheumatoid arthritis (RA). METHODS: Two hundred seventy-nine RA patients (median follow-up 7.8 years) were studied. Of these, 155 patients pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burgers, L. E., van der Pol, J. A., Huizinga, T. W. J., Allaart, C. F., van der Helm-van Mil, A. H. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505077/ https://www.ncbi.nlm.nih.gov/pubmed/31064384 http://dx.doi.org/10.1186/s13075-019-1893-z

Ejemplares similares

ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation
por: Boeters, Debbie M., et al.
Publicado: (2019)

Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis
por: Verstappen, M., et al.
Publicado: (2020)

Response to: “Does ACPA-negative RA consist of subgroups related to sustained DMARD-free remission and serological markers at disease presentation” by Masi and Fleischmann
por: Boeters, Debbie M., et al.
Publicado: (2020)

Correction to: Response to: “Does ACPA-negative RA consist of subgroups related to sustained DMARD-free remission and serological markers at disease presentation” by Masi and Fleischmann
por: Boeters, Debbie M., et al.
Publicado: (2020)

Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study)
por: Heimans, Lotte, et al.
Publicado: (2016)

DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
por: Verstappen, M, et al.
Publicado: (2020)

DAS steered therapy in clinical practice; cross-sectional results from the METEOR database
por: Gvozdenović, Emilia, et al.
Publicado: (2016)

Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial
por: van Mulligen, Elise, et al.
Publicado: (2020)

Aspects of early arthritis. Definition of disease states in early arthritis: remission versus minimal disease activity
por: van der Helm-van Mil, Annette HM, et al.
Publicado: (2006)

Can anti-cyclic citrullinated peptide antibody-negative RA be subdivided into clinical subphenotypes?
por: De Rooy, Diederik PC, et al.
Publicado: (2011)

Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis
por: Akdemir, Gülşah, et al.
Publicado: (2018)

An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression
por: van der Helm-van Mil, Annette H. M., et al.
Publicado: (2013)

Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution
por: Verstappen, M., et al.
Publicado: (2022)

IL2RA is associated with persistence of rheumatoid arthritis
por: van Steenbergen, H.W., et al.
Publicado: (2015)

Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands
por: Matthijssen, Xanthe M. E., et al.
Publicado: (2020)

The earlier, the better or the worse? Towards accurate management of patients with arthralgia at risk for RA
por: van der Helm-van Mil, Annette, et al.
Publicado: (2020)

Substitution of the quantitative serological component in the 2010 criteria for RA with qualitative presence of three autoantibodies yields similar performance: response to the article by Regueiro et al.
por: van Dijk, Bastiaan T., et al.
Publicado: (2020)

Does the presence of magnetic resonance imaging-detected osteitis at diagnosis with rheumatoid arthritis lower the risk for achieving disease-modifying antirheumatic drug-free sustained remission: results of a longitudinal study
por: Burgers, L. E., et al.
Publicado: (2018)

The value of the squeeze test for detection of subclinical synovitis in patients with arthralgia suspicious for progression to RA
por: Wouters, Fenne, et al.
Publicado: (2020)

Rheumatologists’ adherence to a disease activity score steered treatment protocol in early arthritis patients is less if the target is remission
por: Akdemir, G., et al.
Publicado: (2016)

Joint involvement in RA starts predominantly in the hands: functional, clinical and imaging studies in clinically suspect arthralgia and during progression to RA
por: Khidir, Sarah J H, et al.
Publicado: (2023)

ACPA-negative and ACPA-positive RA patients achieving disease resolution demonstrate distinct patterns of MRI-detected joint-inflammation
por: Verstappen, Marloes, et al.
Publicado: (2022)

Health-related quality of life and functional ability in patients with early arthritis during remission steered treatment: results of the IMPROVED study
por: Heimans, Lotte, et al.
Publicado: (2013)

Work participation is reduced during the development of RA, months before clinical arthritis manifests
por: Rogier, Cleo, et al.
Publicado: (2021)

Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets
por: van der Helm-van Mil, Annette HM, et al.
Publicado: (2008)

Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study
por: Akdemir, Gülşah, et al.
Publicado: (2016)

Using a DAS28-CRP-steered treat-to-target strategy does not eliminate subclinical inflammation as assessed by ultrasonography in rheumatoid arthritis patients in longstanding clinical remission
por: Terslev, Lene, et al.
Publicado: (2021)

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
por: Dougados, Maxime, et al.
Publicado: (2017)

Window of opportunity in rheumatoid arthritis – definitions and supporting evidence: from old to new perspectives
por: Burgers, Leonie E, et al.
Publicado: (2019)

Silent progression in patients with rheumatoid arthritis: is DAS28 remission an insufficient goal in RA? Results from the German Remission-plus cohort
por: Sewerin, Philipp, et al.
Publicado: (2017)

Value of imaging detected joint inflammation in explaining fatigue in RA at diagnosis and during the disease course: a large MRI study
por: Matthijssen, X M E, et al.
Publicado: (2021)

Differing time-orders of inflammation decrease between ACPA subsets in RA patients suggest differences in underlying inflammatory pathways
por: Matthijssen, Xanthe M E, et al.
Publicado: (2020)

Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol
por: Mueller, Ruediger B., et al.
Publicado: (2019)

In rheumatoid arthritis patients, total IgA1 and IgA2 levels are elevated: implications for the mucosal origin hypothesis
por: Derksen, Veerle F A M, et al.
Publicado: (2022)

A search to the target tissue in which RA-specific inflammation starts: a detailed MRI study to improve identification of RA-specific features in the phase of clinically suspect arthralgia
por: Matthijssen, Xanthe M. E., et al.
Publicado: (2019)

Functional limitations in the phase of clinically suspect arthralgia are as serious as in early clinical arthritis; a longitudinal study
por: ten Brinck, Robin M, et al.
Publicado: (2017)

What do we measure with 28-joint DAS in elderly patients? An explorative analysis in the NOR-DMARD study
por: van Onna, Marloes, et al.
Publicado: (2020)

Hand function is already reduced before RA development and reflects subclinical tenosynovitis
por: Krijbolder, Doortje Isabelle, et al.
Publicado: (2023)

Is symptom duration before DMARD therapy a determinant of direct and indirect costs in DMARD-naïve RA patients? A systematic review
por: Sahbudin, Ilfita, et al.
Publicado: (2023)

Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment
por: Miwa, Yusuke, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7st91213m0ahbq07vfas613loe